Evidence map›Paper›PMID 41060092›Full record

ArticleJournal of virology2025

Human cytomegalovirus UL78 is a nuclear-localized GPCR necessary for efficient reactivation from latent infection in CD34

Samuel Medica, Nicole L Diggins, Michael Denton, Rebekah L Turner, Lydia J Pung, Adam T Mayo, Olivia Kramer-Hansen, Jennifer Mitchell, Luke Slind, Linh K Nguyen and 8 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Samuel Medica *Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0002-3611-3715
Nicole L Diggins *Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0001-8007-7865
Michael DentonVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Rebekah L TurnerVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Lydia J PungVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Adam T MayoVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Olivia Kramer-HansenDepartment of Biomedical Sciences Molecular Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Jennifer MitchellVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Luke SlindVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Linh K NguyenVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Teresa A BeechwoodVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Gauthami SulgeyVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Craig N KreklywichVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Daniel MalouliVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Mette M RosenkildeDepartment of Biomedical Sciences Molecular Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Patrizia CaposioVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0001-7579-849X
Daniel N StreblowVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0002-6828-2492
Meaghan H HancockVaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0003-2945-0147

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
The Administrative CoreP01AI127335 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio · 2017 to 2026
$24.6M
Molecular Aspects of Cytomegalovirus LatencyR37AI021640 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HANCOCK, MEAGHAN H · 2018 to 2024
$4.0M
Interdisciplinary Training in Microbial Pathogenesis and ImmunologyT32AI170496 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio, Scott M Landfear · 2023 to 2026
$1.5M
NIAID NIH HHS P01 AI127335NIAID NIH HHS R37 AI021640NIAID NIH HHS T32 AI170496NIH HHS AI127335NIH HHS P51 OD 011092NIH HHS P51 OD011092NIH HHS R37 AI21640NIH HHS T32 AI170496-01A1
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that persists throughout the lifetime of the host due to the establishment of latency. HCMV encodes four putative G protein-coupled receptors (GPCRs): US27, US28, UL33, and UL78. A definitive role for UL78 in HCMV infection has yet to be elucidated. Utilizing an IMPORTANCE: Human cytomegalovirus (HCMV) remains one of the most widespread viral infections globally. Primary HCMV infection is typically asymptomatic and leads to the establishment of latency in myeloid lineage cells, where the virus persists for the host's lifetime. Reactivation of latent HCMV can cause severe complications, particularly in immunocompromised individuals, such as transplant recipients and people living with HIV. Several factors influence the transition from latent to lytic infection, including signal transduction through the viral G protein-coupled receptors: US27, US28, UL33, and UL78. Using an advanced

Indexed as

CytomegalovirusCytomegalovirus InfectionsHematopoietic Stem CellsLatent InfectionReceptors, G-Protein-CoupledViral ProteinsVirus ActivationVirus LatencyAntigens, CD34Cell NucleusFibroblastsHumansAntigens, CD34Receptors, G-Protein-CoupledViral ProteinsCD34+ hematopoietic progenitor cellsG protein coupled receptorsG proteinshuman cytomegalovirusstem cellsUL78

Identifiers

PMID41060092
PMCPMC12645970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.